1147
www.klinickafarmakologie.cz340804001076513320121425327329234035839843647950254457164568672477179183988990895196610061045
/26818040010732
Klin275880400107446583131
Farmakol2909804001074279105179220258305325
Farm.3254804001074178105179195
2025;39(2):89-953469804001074487128172185229271295338360375419462491536579
/40938040010731
KLINICKÁ4170804001074588109168189243289347
FARMAKOLOGIE4538804001074291138211266312372415474534555598
A51588040010752
FARMACIE5232804001074191138210265316337380
9556558020012657114
HLAVNÍ4945200012671127198263336370
TÉMA5337200012657114204274
Primum32703600106336886139180234
non351936001063980122
nocere:365736001063979115147182215232
Jak39043600106226196
bezpečná401636001063466100135167202243283
je431536001062254
moderní438536001065192132164200241259
terapie46593600106306298140174192223
roztroušené489836001063374105139175216257289320362394
sklerózy?53083600106306597129165205237276304
26.343640085367187
Oksbjerg4436400834778107146161196217255
NR,712640083458195
Nielsen820640083456095110136171210
SD,1043640083337889
Blinkenberg1145640083365166104134168207246281303341
M,14996400835568
et15816400833456
al.1651640083324760
Anti-CD2017256400834179100116138181226259293
antibody343740083316889103141179217248
therapy603740083225993113145183213
and8287400833168106
risk94674008320356089
of10477400833755
infection1114740083155169103134158172209246
in13727400831551
patients1435740083387091106139176197224
with1671740083496486123
demyelinating18067400833771127157190343840083153068100122137175214
diseases.572840083385380115146173208235248
Mult8368400835492107130
Scler981840083336580115136
Relat1133840083357086118139
Disord.1288840083456187125147185198
2021;52.15018400833468101133141176209222
27.343940085367180
Coles437940083407793128154
AJ,606940083416880
Jones7019400832462101136163
JL,878940083255770
Vermersch963940083366890148183204232264302
P,12799400833640
et13349400833456
al.1405940083324760
Autoimmunity14809400834178100137152210268306344359381415
and19109400833169108
long-term3431040083155391130153175209230289
safety6491040083265978113135169
and83510400833270109
efficacy962104008334527088120153185218
of119810400833756
alemtuzumab12721040083324782140161199229267325357396
for16861040083185677
multiple178110400835795110133148187203238
sclerosis:3431140083265874108130167194209235247
Benefit/risk60511400833570108143161178200228247263289319
following938114008319567287126177192230269
review12221140083205487102137188
of142511400833756
trial1496114008322435991106
and161711400833169108
post-marketing1740114008339771041271472062382593431240083306486101139178
data.5371240083387092124138
Multiple69012400835592108130145185200235
Sclerosis9411240083326480115136173200215241
Journal.119712400832462101122160193208221
2022;28(5):842-846.143312400833468101136148183217236270288300335371404424460496532546
28.3431340085367288
Kim44713400833551109
T,57213400833341
Brinker6291340083365773111141175196
A,84113400834155
Croteau9121340083406198120154186223
D,115113400834656
et122313400833457
al.12961340083314760
Immune-mediated137213400831472130168206241264323358397412444466500539
colitis19271340083316834314400831530526894
associated4511440083325985123156171203225259298
with7641440083506688127
ocrelizumab:9051440083387091126141156185223281314353365
A1285144008341
new134014400833873124
safety14791440083265978112135168
risk.1662144008321366292107
Multiple178414400835492107130145184200235
Sclerosis3431540083326580115136173200215241
Journal.59915400832563101122161193208221
2023;29(10):1275-1281.83615400833468101136147182216235267298317329358388421454476507537571602612
29.3431640085367285
Maunula44516400835487125163200215248
A,70916400834155
Atula78116400834162100115147
S,94516400833245
Laakso10061640083326598128157195
SM,121716400833387101
et133416400833456
al.14071640083324760
Frequency14831640083335286126164198237269302
and180216400833169108
risk1927164008321366292
factors3431740083185082105141162188
of54317400833755
rebound6101740083215492130167204242
after8641740083314973106127
fingolimod10031740083163370108145160174231268307
discontinuation13221740083375277108144181202217254290322343357394432
–1766174008334
A1812174008340
retrospective186417400832154759613234318400832665101133157173205240
study.5981840083264987126158168
Mult78118400835593108130
Scler9271840083326580115136
Relat10781840083367186118140
Disord.12331840083466187126147185199
2024;81:105-134.144718400833468101133145180212220250282316338369398434446
30.3431940085367287
Lee44219400833165100
JD,5551940083247081
Chen64919400834077112150
T.81219400833241
Natalizumab8661940083457798131146161190228286318357
Rebound123619400833570109147185223262
in151119400831452
Multiple157619400835492107129144183199234
Sclerosis.18231940083326479114135172343204008326416781
Neurohospitalist.43920400834580117139176214253279318334356389404419446469482
2021;12(1):197.93620400833569101133141171201219250265277306337369376
31.3432140085376879
Goh43921400834482119
LY,5752140083326269
Kirthi661214008335507093130143
V,82121400833644
Silber882214008333465997131151
E,105021400833345
et111221400833455
al.11842140083324658
Real-world125821400833670101115135186223243257295
incidence1570214008315518296133167204235267
of185421400833856
fingolimod-associated192721400831734713432240083397589102159196234254285310335372403416447467499537
macular89622400835889120156170200220
oedema.113222400833872110143200231242
Mult139122400835591105126
Scler15332240083336477111130
Relat16802240083366983113134
Disord.18302240083466084121141177189
2020;42:102-125.3432340083346697129140172203213241270301319348376409418
32.3432440085367186
Kappos44724400833568108147186213
L,67724400833245
Fox74024400833270100
RJ,8572440083366375
Burcklen9492440083367495126156172207245
M,121224400835468
et129724400833457
al.13712440083324760
Ponesimod144924400833572110145172187245283322
Compared1789244008340771351742073432540083215594
With4562540083577396134
Teriflunomide6082540083336384100118135172210249307322361396
in102225400831553
Patients10932540083356789104139177198226
With13372540083587496134
Relapsing14902540083357086118157184198236275
Multiple178425400835492107130145184200235
Sclerosis3432640083326480114135172199213239
in59526400831452
the6602640083215994
Active-Comparator7672640083407296111143177200242279337376409430462484521542
Phase132226400833572104130165
31500264008334
OPTIMUM154626400834783117133187231285
Study:18442640083325391130162175
A343274008341
Randomized39627400833568105144182240255283317356
Clinical7652740083395469107121153186201
Trial.978274008333506597112124
JAMA111527400832464119160
Neurol.128827400834479116137174190202
2021;78(5):558-567.150327400833468100131139172205224257275287322354387410443477510516
33.3432840085367084
Pierret4392840083354983104125158180
C,63128400834052
Mulliez69628400835491106120135169198
A,90628400834154
Le97328400833164
Bihan-Benjamin10492840083355088119157178215249287302333390405442
C,150328400834052
et156728400833456
al.16352840083324659
Cancer170628400834072109141174195
Risk19132840083355076105
Among34329400834097134171209
Patients5642940083356586101135172192219
With7952940083567293131
Multiple93729400835491105127141179195228
Sclerosis:11772940083326378112132168194208234245
A1434294008341
10-Year14862940083346487119149180200
Nationwide16982940083447696111148185234249287321
Retrospective3433040083357091112149175214249281305320352386
Cohort74130400834076114152173197
Study.9513040083325390129160170
Neurology.113330400834579117137174190227266298308
2024;103(9):e209885.145330400833467100131143172203236254286303315349383417451486521554566
34.3433140085367388
Kingwell4473140083355189128180214230245
E,70831400833245
Bajdik7693140083366984123138168
C,95331400834053
Phillips10223140083357287103118133172199
N,123631400834558
et131031400833456
al.13823140083324760
Cancer145831400834073111143177198
risk1672314008321366292
in178031400831553
multiple1849314008357941101321473433240083395589
sclerosis:4493240083265874108130167194208234247
Findings7123240083334886125140178217243
from9713240083194178136
British1124324008335567295110136174
Columbia,13143240083407793130188228243275288
Canada.161832400834073111144183215228
Brain.18633240083355689105142156
2012;135(10):2973-2979.34333400833468100130142172202235253285316335346382416449483505536570603636647
35.3433440085366983
Nørgaard43734400834481102139170201221258
M,70634400835466
Veres7833440083356787120145
K,93934400833548
Sellebjerg999344008332658094128165180213233270
FT,12803440083326674
et136534400833455
al.14313440083314658
Incidence1500344008314518296133167204235267
of177834400833755
malignancy18443440083578810311615434335400833869106138171
in52735400831452
multiple59235400835794109130145183199233
sclerosis:8383540083265872106127163189203229241
A1092354008341
cohort114635400833167105143164188
study13473540083264886124155
in151535400831552
the15803540083225994
Danish168735400834577114128154191
Multiple189135400835592106343364008322367590124
Sclerosis4813640083326479113133170196210235
Registry.73036400833670109123149171192225234
Mult97836400835592107128
Scler11203640083336479113134
J1267364008325
Exp130636400833264103
Transl14233640083324981118144159
Clin.15963640083395468105118
2021;7(4).172836400833467100130138170186218235245
36.3433740085367288
Liu4483740083314784
Z,54937400833851
Fan6183740083326199
T,73537400833241
Mo79337400835593
X,90337400833952
Kan97237400833569107
J,109637400832436
Zhang114937400833876108146185
B.135137400833649
Association14173740083416995134166182214235251289327
between17613740083397497150184220258
multiple34338400835795110133148187203238
sclerosis5973840083265873108129167193208234
and84738400833270109
cancer97238400833164102134168189
risk:1177384008321376393107
A1300384008341
two-sample135738400832275113136163196254293309344
Mendelian171738400835489127166201217232264302
randomization3433940083215492131169227242271305327342380418
study.7773940083264987126158168
PLoS96039400833566104136
One.111139400834786121133
2024;19:e.125939400833468101133145175205218253265
37.3434040085367079
Marrie43740400835487108130146180
RA,6324040083357892
Cohen73940400834077116151189
J,94340400832436
Stuve9944040083325391124158
O,116740400834758
et124040400833456
al.13114040083324760
A1386404008341
systematic14424040083265885109142200233254270302
review17584040083215587103138189
of196240400833756
the3434140083226095
incidence4514140083155385100139173212244277
and74241400833169108
prevalence8644140083386094126159175209248280313
of119141400833756
comorbidity126041400833268127165187226242281296318352
in162541400831553
multiple169141400835795110133148187203238
sclerosis:1942414008326583434240083155071108135150176188
Overview.54742400834780114136170186221272283
Mult84542400835592108130
Scler.9904240083336580115137147
2015;21(3):263.115242400833468100130141176207222256273285320354388400
38.3434340085367187
Grytten4424340083436498122146179217
N,67143400834557
Myhr74143400835485123143
KM,89743400833490103
Celius10134340083397388102139165
EG,11914340083327589
et129243400833455
al.13604340083314659
Risk14324340083355075105
of154943400833756
cancer161743400833164101133166187
among181643400833289127164203
multiple34344400835897112135151191207243
sclerosis6074440083265975111133171198213240
patients,8684440083397395111146185207236249
siblings,1138444008327428298114152192219232
and139144400833372111
population152344400834079120159175207230245284324
controls:1868444008331691081303434540083215874100112
A474454008341
prospective5334540083396097124163199231255271303338
cohort88945400833168107145166191
study.10984540083265088127159169
Multiple128545400835492108130145184200235
Sclerosis15384540083336581115137174201215241
Journal.179845400832462100122160192208221
2020;26(12):1569-1580.34346400833468101135148183217236267297315327357387421455479509540574609622
39.3434740085367185
Jiang4444740083243971109148
M,60947400835467
Lam69347400833165122
L,83247400833145
Zhuang89347400833876113145184223
YZ,11324740083357588
et123647400833456
al.13094740083314760
Incidence13854740083155385100139174212244278
and167947400833270109
Characteristics180447400834078110131164196343484008322557792118141157189216
of57848400833857
Melanoma65448400835590105137175214272304
in97748400831553
Multiple104948400835492108130145184200235
Sclerosis13034840083336580115136173200215241
Patients15634840083356789104139177199226
Treated18084840083335084116138171211
With3434940083577496134
Fingolimod:4964940083324785124162178193251289329341
A856494008340
Systematic9154940083336289113146204237258274306
Review.123949400833671103119153204215
Curr14734940083407697119
Dermatol161149400834580102160192214251267
Rep.189749400833570109122
2023;12(4):300-313.34350400833468101136147177207225258275287322357393417449480510522
40.3435140085367489
Riederer4505140083355186125160181215237
F.70551400833239
Ocrelizumab76251400834780101135150165195233291323362
versus11435140083316587114151177
placebo13395140083385487119152192230
in158851400831452
primary16595140083386076133166187221
progressive189851400833960983435240083385992119145160192226
multiple58252400835794109131146185201235
sclerosis.8305240083265873107128165192206232246
Journal108852400832462100121159191206
fur13075240083185677
Neurologie,139752400834479116137174190228267282316328
Neurochirurgie1738524008344791161371742062442593435340083215980118133168
und52653400833876115
Psychiatrie.6565340083356194125163178210232254269304316
2017;18(1):30-31.98753400833569100130140170201220251266278313347371404435444
41.3435440085366981
Nielsen4405440083456095110136171209
NM,666544008345100113
Rostgaard79654400833674101124162194226247286
K,109954400833449
Rasmussen11655440083366895152190216243278316
S,149854400833345
et156054400833457
al.16345440083314760
Cancer171154400834072110143176197
risk1925544008321376393
among34355400833289128166205
patients5615540083397293108143181203230
with8045540083516689127
multiple94455400835795110132147186202237
sclerosis:11945540083265873108129167193208234246
A1453554008341
population-based150755400833978117155171203224240278316338378411438473512
register3435640083215594109136159192214
study.5725640083264987126158168
Int7565640083145274
J845564008324
Cancer.88556400834072110143176198208
2006;118(4):979-984.110856400833468105140153183210241260293311323358391424448483518554566
42.3435740085377289
Kappos45357400833670111151191219
L,69357400833247
Li76157400833248
D,83057400834758
Calabresi9095740083417591124165187222250265
PA,11965740083367489
et130657400833558
al.13855740083334962
Ocrelizumab146957400834881103138155170200240299332373
in186357400831554
relapsing-remitting1939574008321563435840083154991119135175216240264300360377401427443483524
multiple89558400835998115139156197214251
sclerosis:11735840083276178115137177205221249263
A1463584008342
phase153358400834080114143179
2,174058400833549
randomised,1816584008321569613717821386400835975102139180193
placebo-controlled,2353640083395690123158199239264299337377400422461478494530571584
multicentre29596400835998114138154187222262284307342
trial.332364008322456194111124
The34696400833374111
Lancet.36016400833267107140175199213
201;378(9805):1779-1787.21387400833468100108143175209228260295331365383395425454489522546576606639672678
43.2138840085367186
Hauser22388400834476114140175196
SL,2447840083336477
Bar-Or2537840083366990109159181
A,27318400834155
Comi27998400834077135150
G,29628400834457
et30328400833457
al.3102840083314760
Ocrelizumab31758400834679100134150165194232290322361
versus3549840083326687115152178
Interferon37408400831553213894008321547596130151187225
Beta-1a2375940083357092124146176204
in25919400831452
Relapsing2655940083356984116155181195232271
Multiple29389400835491106128143181196231
Sclerosis.3181940083326479113133170196211236249
New34439400834478129
England35849400833269107122154191230
Journal213810400832462101122160193208
of236110400833857
Medicine.243310400835590129144176192229264277
2017;376(3):221-234.272510400833468100129139174206238257291308320355390421440471506541553
44.21381140085367184
Hauser223111400834473108132164183
SL,24231140083326071
Kappos250311400833465102139175199
L,271011400833143
Arnold27611140083405995131144181
DL,29501140083457486
et304411400833353
al.31061140083314455
Five31691140083324474106
years32831140083316292110135
of342611400833754
ocrelizumab34881140083376786118131143170205260290327
in213812400831550
relapsing2197124008320526696132157170205242
multiple244812400835792105125138175189221
sclerosis:26781240083265669102121156180193217227
OPERA291412400834680110143184
studies31071240083264782119132164189
open-label330512400833774107143163178207244278291
extension.3605124008334638511615217618921381340083377485
Neurology.223413400834477113132167181217255285292
2020;95(13):E1854-1867.25381340083346697129139173205220250278293302334363392424457478507536569600604
45.21381440085367186
Kappos223914400833568108147186213
L,246614400833145
Traboulsee25251440083335083122161199215241276311
A,285014400834155
Li292014400833146
DKB,298114400834581118130
et312614400833456
al.31961440083324760
Ocrelizumab327114400834779100135150165194232290323362
exposure36471440083346610514421381540083266384119
in227115400831553
relapsing-remitting23391540083215570102142168183221260282304338396411434458473511550
multiple290415400835895111133148187203238
sclerosis:31571540083265874108130167194209235247
10-year34191540083346689121156188209
analysis36431540083316910211714921381640083264167
of221916400833757
the22901640083216095
phase239916400833877109136171
22584164008334
randomized26321640083215492131169227242271305345
clinical2991164008331466199114146179195
trial3200164008321435890106
and332016400833270109
its34431640083143765
extension.35221640083346589123161188202240279292
J2138174008324
Neurol.217717400834580118139176192205
2024;271(2):642-657.239717400833569102133145180213246261295313325360396429449487520554560
46.21381840085367388
D’Amico22391840083455894152166197234
E,248518400833345
Chisari25421840083407892117150170185
CG,27401840083408193
Arena28461840083416195132164
S,302218400833345
et307918400833456
al.31471840083324759
Cancer321818400834072110141174195
risk3425184008321366190
and352818400833269107
multiple36481840083579410913014521381940083395488
sclerosis:22411940083275873107127164190204230241
Evidence24981940083326479117151188220253
from27661940083194077134
a2916194008331
large29631940083154667104138
Italian311719400831536688397129166
cohort.329819400833268106143164188201
Front35141940083325188126147
Neurol.3676194008345791162138204008321577285
2019;10(APR).22372040083346798128140169200219259294329347357
47.21382140085366976
Ryerson222521400833567100119145182219
LZ,24542140083317082
Foley25462140083326883116146
J,270221400832435
Kister2747214008335507596129148
I,290621400831426
et294221400833455
al.30072140083324657
Reduced307421400833669107143174206244
Risk33292140083354974102
of344121400833855
Progressive35072140083355490128148180206231244275308
Multifocal213822400835389102122136153188218249262
Leukoencephalopathy24092240083316398126161194230259291327364393407442480510530565594
(PML)301222400831851102132149
with31702240083506384119
Natalizumab32992240083447493124137150177212267297334
Extended36422240083326285116152213823400833872110
Interval22602340083145171103123157188202
Dosing247423400834583108121158195
(EID)26812340083195064108124
Compared281723400834076133171202222255293
with31222340083506485122
Every-4-week32562340083336396116148169204226276309343372
(Q4W)36402340083186398154174
Dosing:213824400834583108121158195206
Updated235824400834481119150170203241
Analysis261224400834178109123153179192217
of284324400833755
the29112440083225992
TOUCH®301724400833277121160203230
Prescribing32612440083355487112143163177215229266303
Program35782440083355490128148180236
Database21382540083457696128166197222256
(P10-6.005).24072540083185283113136172184217252285302311
Neurology.273125400834478114134170184221259290299
2024;102(17_supplement_1).30422540083346798129139168198230246276304333359395433471486519576609646666702732745755
48.21382640085367490
Štourač22442640083325390128150183215
P,247426400833540
Bednářová253026400833570110148180201238270303
J,284926400832436
Pavelek29012640083356798133148183213
Z.313026400833851
Etiopathogenesis31972640083335469107147180201239278317352390425452467493
and370626400833270109
diagnostics21382740083385385124162201227250266298325
of247827400833757
progressive25502740083386097137158192219245260293327
multifocal289227400835795110133148167205237270286
leukoencephalopathy31932740083144987117155190228260294333372404419458497530552590621
in213828400831552
patients22032840083387192107141179200228
treated24432840083224376108129163202
with26572840083516688126
natalizumab.27962840083376990122138152181219276308347359
Ceska31682840083397399129162
a3342284008332
Slovenska33872840083324785116150188214243276
Neurologie36762840083447911621382940083215874112151167201
a2355294008331
Neurochirurgie.240229400834479117138176208246261282321342380395430442
2021;84(2):135-138.285929400833569101133141176213232266284296326356389411442471506519
49.21383040085367285
Bou223630400833574112
Rjeily23613040083355185101116148
N,252230400834457
Fitzgerald25923040083324770101139173195228243282
KC,28873040083357487
Mowry298730400835493144165199
EM.319930400833388102
Extended33143040083336590123161200235275
interval36023040083145274108129164196212
dosing213831400833876103118156195
of235131400833857
ocrelizumab24263140083387092126141156185224281314353
in279831400831452
patients28693140083387193108143181203231
with31183140083516689127
multiple326431400835794110132147187202237
sclerosis35203140083265874108130167194208235
is377331400831541
not21383240083377597
associated22483240083325884122155170202223257296
with25573240083506688126
meaningful269632400835792123161176214252272310325
differences3034324008338537391126147181218250284310
in335732400831552
disease34223240083385379114146172207
activity.3642324008331638710213515021383340083225565
Multiple221933400835492107130145184200235
Sclerosis24693340083336580115136174200215241
Journal.272633400832462100121160192208220
2024;30(2):257-260.296233400833468101133145180214234268286297333367401419450484519532
50.21383440085367186
Serra22403440083326787108141
López-Matencio239634400833268107142171192247279300333371402417454
JM,28663440083247891
Pérez29723440083366889122151
García31393440083447696126141172
Y,332734400833543
Meca-Lallana338534400835589121153175207240255269301338370
V,377134400833543
et213835400833456
al.22113540083324659
Evaluation22873540083336496111147179200215252290
of259435400833756
Natalizumab26673540083457798130144159187225282313352
Pharmacokinetics303635400833572104124182214245281311327364398420435466493
and354635400833269108
Pharmacodynamics:367135400833572103124213836400835890122158198229268300357372404431443
Toward260036400833367118150171209
Individualized28283640083155391106138153192229261276291319353392
Doses.324036400834584110145171184
Front34443640083325188127148
Neurol.361136400834580117138175190203
2021;12:416-548.213837400833468100130138167197208242272302325358393428441
51.21383840085377285
Tran22453840083335186125
TDQ,239238400833382132146
Hall25603840083457995111
L,269238400833347
Heal276138400834581114130
C,291338400834155
et298938400833559
al.30693840083334963
Planned31533840083365285125164200241
dose341638400833979106143
reduction35803840083225798137170195211213839400833877
of223639400833858
ocrelizumab23153940083387193128144159189228287320360
in269639400831554
relapsing-remitting27713940083215672105145172187226266289311346405421444469484523563
multiple335539400835897112135151191207243
sclerosis:361939400832760751111331712138404008326416780
a2239404008332
single-centre22914040083264179119134169192226260298320342376
observational268740400833878104140161196229251266305343376391
study.30994040083264988127159169
BMJ328940400833590116
Neurol342640400834580118139177193
Open.363940400834888123162175
2024;6(1):672.213841400833468101133145181200231246258293326360373
52.21384240085367187
Shirah22394240083327085106139178
BH,24304240083358093
Algahtani25374240083415695127165187220258273
H.282342400834458
Personalized28944240083366990117156194226242257286320360
Half-Dose32674240083447692111132179217244279
Ocrelizumab356042400834679100134150165194232213843400835790129
in228043400831452
Selected23454340083336883118151175209248
Patients26064340083356789104139177198226
with28454340083506688127
Relapsing-Remitting29854340083357085118157183198236275297334369427442465489504542581
Multiple357943400835592108130145184200235
Sclerosis.21384440083326580115136173200215241255
Mult240844400835492108130
Scler25534440083336580115136
Relat27054440083357086118140
Disord.28604440083456187125147185198
2023;71:104349.307344400833569101136148181213222251283319352387420431
53.21384540085367186
Scavone22374540083326598129167205240
C,249045400834053
Anatriello255645400834180112134155171205221236274
A,284345400834155
Baccari291245400833568100131164185201
I,312645400831427
et316645400833457
al.32364540083324760
Comparison330945400834077135174207228244270308347
of366945400833757
injective37394540083145221384640083155082107122154189
related23434640083215570103124158198
reactions25574640083215587119143158196235261
following2834464008319567287126177192230269
ofatumumab31204640083375690111149207245303335374
and351146400833169108
ocrelizumab36364640083377091125141156213847400832866124157196
in234947400831553
patients24174740083397293109143182203231
with26634740083516689127
multiple280547400835795110133148187203238
sclerosis:30584740083265974109130167194209235247
data33214740083387092125
from34614740083184078136
the36124740083226095
European37224740083337021384840083215897133165203
spontaneous236048400832665104143164197235270309347373
reporting27524840083215594133155179195232271
system.30434840083265885109142200213
Frontiers32764840083325289127149164199220247
in354348400831452
Neurology.36144840083458011813917621384940083155393125135
2024;15:1383910.228849400833468101133145175205216246276310344377409441453
54.21385040085367286
Newsome224250400834579129155192249283
SD,25435040083327686
Krzystanek26465040083355786119145167198235269298
E,296250400833344
Selmaj30245040083336781138169183
KW,322550400833594102
et334550400833455
al.34185040083324658
Subcutaneous34945040083326910613817519622826429821385140083377499
Ocrelizumab22525140083477898130145158186223279310348
in261551400831451
Patients26815140083356586100133170190216
With29125140083577293130
Multiple305751400835491104125139177192225
Sclerosis:32975140083326377111130166192205230241
Results35535140083356994130144165191
of375951400833755
the21385240083225892
Phase224352400833571102127160
32416524008334
OCARINA246352400834786128162177220260
II273652400831428
Study.27775240083325289126157165
Neurology.295552400834578115134170185221260290299
2025;104(9):e213574.32665240083356799132141170200235253284301311344377407436468500529540
55.21385340085356983
Theil223353400833270104118133
D,237753400834555
Smith244453400833288102124161
P,261653400833539
Huck266753400834379110139
C,281853400833952
et288153400833455
al.29485340083314658
Imaging301853400831470102139154191228
mass325853400835688113139
cytometry34095340083306386122179213234255288
and370853400833268106
single-cell21385440083264077116131165187220253268283
genomics243354400833872110147204219250278
reveal27235440083205485119150165
differential2900544008338537291124145179216237252283298
depletion321054400833872111126160182197234272
and349454400833269107
repletion36145440083205392107142163178213855400833775
of222555400833756
B-cell22945540083355790124139154
populations246055400833877116154169200222237274312338
following2810554008319567186124174189227265
ofatumumab30885540083375688110147204242299331369
treatment34705540083214276107129186221258279
in376255400831452
cynomolgus213856400833165104142200238254293331357
monkeys.250956400835796134164198230257270
Front27935640083325289128149
Immunol.295656400831573130168206244260273
2019;10(JUN):453167.324356400833468100130143173204224249293339357369404437470500532565571
56.21385740085367286
Szepanowski22385740083326094132165202239290316345361
F,261257400833237
Warnke266257400835788108146176209
C,288457400834052
Meyer294957400835489120153174
zu313657400832865
Hörste321457400834482103129152185
G,341157400834457
et348157400833455
al.35495740083324659
Secondary3620574008333679913517321385840083386888121
Immunodeficiency227058400831470127163199236274308324341371385418455486518
and279958400833168105
Risk29155840083354974102
of302858400833755
Infection30945840083155169102133156170206243
Following3348584008332688397133183197233271
Immune36305840083147012616339346400833872
Therapies40206400833271105126158196211245271
in43056400831552
Neurology.43716400834579116137173188226265296305
CNS46906400834084116
Drugs.48206400834566104142168180
2021;35(11):1173-1188.50146400833568100131138173205222253280294305334361390423444474501532566579
57.3934740085367179
European4026740083326990127166201233271
Medicines43097400835589129144175190228263289
Agency.46117400834179113151183216226
Guideline4850740083438196135169185200237272
on51357400833775
the5223740083215994
clinical532974008332476199114146178194
investigation553574008315523934840083326693116131170202224239277316
of42708400833756
human43468400833775133165203
normal4569840083377697156188203
immunoglobulin47928400831572130168206244284299337377415430445483
for5295840083185677
intravenous53928400831553749612916019439349400833775112138
administration40849400833170127141179193219241262295316331368406
(IVIg).450294008318336985123141152
2021.4666940083346799130139
Available48189400834070102117132163202217251
from:5082940083183976133145
https://www.5239940083375882121147159185205255308360371
ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-human-normal-immunoglobulin-393410400833492124137172210231268308341354389427453484522548584622655693750785823845873898923955970100510431064107910971114114611651205124312581297133213471362140014351461149715341549158816231639165439341140083387396130145160198213246279294316333371402437463487502541574595611649688710749787845878916938977101610381096112911441167118312411299133613751413145314681507154615851600161516531676
-intravenous-administration-ivig-rev-4_en.pdf.393412400832137759611815118221725529333135737841145050852356157660262564667970171675479381583186488091894196399710291051108811241160119812111251129013101321
58.39341340085367288
Buljevac40411340083357389104139171204236
D,429513400834657
Flach43701340083324779112149
HZ,45381340083448295
Hop465213400834482122
WCJ,479213400835898124136
et494713400833456
al.50221340083314760
Prospective51001340083355693120159195227251267299333
study54521340083264987126158
on393414400833776
the40231440083226095
relationship41321440083215570102124139177216242280295334
between44801440083397496149184219257
infections47511440083155371106139163178216254281
and504514400833270109
multiple516814400835795110133148187203238
sclerosis5419144008327597410913016739341540083264167
exacerbations.40161540083346699131164186225258280295333372398412
Brain.44431540083355790105143156
2002;125(5):952-960.461415400833468105138150180210245262296314326361396429449484519555567
59.39341640085356981
Stastna40261640083325283108130167198
D,423516400834554
Menkyova430016400835488124153185222252284
I,459416400831527
Drahota46311640083456697134171191223
J,486416400832435
et491016400833455
al.49751640083324658
To504416400833264
be511916400833872
or520216400833757
not52701640083377495
to537516400832257
be544316400833872
vaccinated:55261640083316339341740083316175112144165197236247
The419317400833271105
risk4309174008321366190
of441017400833756
MS447717400835487
or457517400833758
NMOSD464417400834599146177221
relapse48771740083205468100138164198
after50861740083325074107127
COVID-19522517400834084119134179202232261
vaccination5498174008331639439341840083314582113134148185223
and416818400833269107
infection.42861840083145169102134157172209246258
Mult455518400835591106127
Scler46931840083336478112132
Relat48371840083356983115135
Disord.49841840083455984122142179191
2022;65:104014.51871840083346799132144178211221250280316350381411423
60.39341940085367387
Mailand403419400835486101116148185224
MT,42711940083548796
Frederiksen43791940083325285125159180195225254288326
JL.47171940083245670
Vaccines47991940083366798129144181216242
and505419400833169108
multiple517419400835794110132147185201235
sclerosis:542219400832658731071281653934204008326416780
a4027204008332
systematic40732040083265986109143201233255270302
review.43892040083205487102137188199
J4602204008324
Neurol464020400834580117139176192
[Internet].4846204008318347293127148187222244262274
2017;264(6):10351050.513420400833468100129139174207244263297315327356388421454393421400833466100134146
61.39342240085356879
Horakova402622400834381102134163200231263
D.430122400834556
Doporučení436922400834482121159180217248281318333
Výboru471422400833567106143164202
Sekce49282240083326696126159
klinické5099224008329456097111142172205
neuroimunologie53162240083377110812816518023627339342340083387895134175191227
a4182234008333
likvorologie4236234008316316298137160198215254295311347
ČNS460423400834188121
ČLS474723400834173109
JEP.48772340083256096102
2021.500023400833571105137147
Available516923400834273107123139173213230266
from:54562340083194281141154
www.aktivnizivot.cz.3934244008351104157168202232257272304343358387403436473495508540571585
62.39342540085367187
Meltzer403425400835489105127157191212
E,425925400833245
Campbell431725400834073130169208244259274
S,460425400833245
Ehrenfeld46622540083327091124162181215231269
B,494425400833548
et500525400833456
al.50732540083324760
Mitigating51462540083546992107145177199214252291
alemtuzumab-associated5449254008332478213939342640083226089127185217257280312339365404436451483505539579
autoimmunity45262640083316992129144202259297335350373406
in494526400831553
MS:50112640083558899
A5123264008341
‘whack-a-mole’517826400831263102134166196216249271330368384419432
B-cell39342740083355892126142157
depletion411127400833873113129164186201240278
strategy.44102740083264971104126159199231241
Neurology(R)467227400834580118139176192230270302322358376
neuroimmunology506927400833873111132169185243301338376415431469509541
&3934284008339
neuroinflammation.398928400833772110131168184222239256288346404436458473511550563
2020;7(6):e868.456728400833468101135148181197231249261295330366401414
63.39342940085377388
Bierhansl40432940083365287108147180219246261
L,432429400833246
Hartung43902940083457899124163202241
HP,46512940083468286
Aktas47572940083427398131158
O,493529400834859
et501429400833558
al.50922940083324861
Thinking51732940083337388127157174212252
outside544529400833877100128143393430400833873
the40263040083226094
box:413930400833978108121
non-canonical427930400833876114136169202239277315330361394409
targets47073040083225475112147169196
in492230400831552
multiple499430400835795109131146185200235
sclerosis.52483040083265873107128165191205231244
Nat55113040083457799
Rev393431400833670102
Drug405531400834667105143
Discov.42183140083456086118154186195
2022;21(8):578.443231400833568101135147181212227260278289324357390403
Available485431400834171104118133165204219253
from:51273140083184076134146
/pmc/articles/PMC9169033/.52923140083256212015217920922925326830039343240083154975100136189229262293324357392424457480485
64.39343340085367591
Greenberg404733400834467101138177217253275314
BM.438233400833692106
Bruton’s45103340083355797120157197209235
Tyrosine47663340083336184122149165204239
Kinase50263340083365392125152188
Inhibitors52353340083155492108148164187225247275
for55313340083195779
Multiple393434400835594110133148188205240
Sclerosis41953440083336682118140178205220247
Treatment:44633440083335186118140200235274296310
A4794344008342
New485734400834581133
Frontier.50123440083325391130152168203225236
Neurol526934400834581119141179196
Clin.54863440083405671110124
2024;42(1):155-163.393435400833468101133145180212229261276287317347380402433464498510
65.39343640085367286
Study40383640083325492131163
Details421836400834681103136151166192
|4428364008315
Peptide-coupled446136400833568108130145184219242276312351390406440480
Red495936400833570110
Blood50863640083365190128168
Cells52723640083407389104130
for54203640083185677
the55153640083226095
Treatment39343740083335084116137196231269290
of424237400833756
Multiple431637400835492107130145184200235
Sclerosis45683740083336581115137174201215241
|4827374008315
ClinicalTrials.gov.48593740083405570108123155188204238255270302318344357396434466476
Available535337400834171104119135167206222257
from:39343840083184078136148
https://clinicaltrials.gov/study/NCT06430671.40983840083375983122149162188209238253268306321353386401423445460492508534547586624656680704727765804836860905946982101610521088112111551191122412561266
66.39343940085367389
Rush40383940083357399137
CA,41903940083398296
Atkins43013940083416292109146173
HL,44883940083447690
Freedman45923940083335286122161219252290
MS.489639400835487101
Autologous501139400834178101138153192231269307334
Hematopoietic53593940083447913717019122839344040083387691125146161192
Stem41394040083325285142
Cell42934040083397287102
Transplantation44074040083324981118144182197229266287319340354392429
in484840400831552
the49124040083215993
Treatment50174040083324982113134191225263283
of531340400833655
Multiple538040400835491106127142180196230
Sclerosis.39344140083326479114135172198213239252
Cold41994140083407692131
Spring43424140083337193108146184
Harb45394140083447697136
Perspect46884140083356889116155190223246
Med.494741400835489128141
2019;9(3):a029082.51014140083346899129142177196229246258291326358392428463496509
67.39344240085367179
Gupta403142400834482121143176
S,422442400833345
Seshadri42874240083326794132164203224240
M,454442400835568
Lincoln46294240083324785117154170208
R,485442400833549
et492142400833456
al.49944240083324760
An507242400834179
Investigator51684240083155384118145168184222255276313335
Initiated552042400831553683934434008322376991124164
Study41144340083335492131163
of429343400833756
KYV-101,436643400833473112133164195227236
a4618434008332
CD19466643400834085117147
CAR482943400834083119
T4964434008333
Cell50134340083407389104
Therapy,513343400833372107128161200232241
in539143400831452
Participants5459434008335678811312839344440083314685118156178206
with41594440083516789127
Treatment43064440083325084116137195231269290
Refractory46164440083357089112144177201238259293
Progressive49294440083355693133154188215241256289323
Multiple527244400835492107130145184200235
Sclerosis55274440083326439344540083155071108135150176
(S3.002).4125454008319508497132168201219230
Blood.43704540083355189128167181
2024;144(1):3469.1.456645400833468101133145175206243262294308320356391427461472503512
68.39344640085367592
Tiziana4048464008333518198131170203
Life42744640083314868104
Sciences44004640083336682118157191226254
Announces467646400834181120159199238271306334
Johns503246400832564104143170
Hopkins522546400834484125156174213240
University5488464008344839939344740083326891119135159194
Commences415147400834179139199236275309344373
Dosing454647400834687115131170211
Nasal477947400834680108142159
Foralumab49614740083337194129146185244278319
in530347400831554
Phase538047400833574108136173
25575474008335
Multiple393448400835593109132149188205241
Sclerosis41974840083326581117139177205220247
Clinical44664840083405672111126159193209
Trial46974840083335167100116
–4835484008335
Tiziana4892484008332508096129168201
Life51154840083314868103
Sciences52404840083326681117156189223251
[Internet].5513484008318357439344940083225678117153176194207
Tiziana4163494008332508096129167200
Life43854940083314868103
Science.45094940083336682117156189223236
Available476749400834172106122137170210227262
from:50514940083194179138151
https://www.52244940083386085125152166193214266320374386
tizianalifesciences.com/tiziana-life-sciences-announces-3934504008322396986120160194211227248284312346363399439473508537551585624684712736752783800834874908932949966986102210471076111011261162120212361272130013221356139614361476151615561590162516541676
-johns-hopkins-university-commences-dosing-nasal-foralumab-in-phase-2-multiple-sclerosis-clinical-trial/?utm_39345140083213979119159187209250290332364382421449472512552569603639662690707731766790825864924984102110611095113011591181122312631292130813481389141214531487151515501567159016121651393452400832154701091672002402642813193433834234564835185425745956546937097327487878048408638919249409759971035106310781105112711611177119312311247128013131329135213751397141414461463148915181556157916381676
source=chatgpt.com.393453400832665104126157192236270309342364403443465479512550609623
69.39345440085367285
Vermersch40335440083366890148183204232264302
P,434854400833640
Granziera44025440083436598136165181216237270
C,468654400833952
Mao-Draayer475254400835587125149196217250283313348369
Y,513554400833543
et519254400833456
al.52625440083314760
Inhibition53355440083155391106145161183199236275
of393455400833756
CD40L400355400833984120156188
with42045540083506587125
Frexalimab43425540083325185116149164179236268307
in466155400831552
Multiple472655400835492107129144183198233
Sclerosis.49715540083336580114135172198213239252
New523655400834479130
England537855400833370109124156193232
Journal393456400832462101122160193208
of415756400833857
Medicine.422956400835590129144176192229264277
2024;390(7):589-600.452156400833468101133145180213249268303322334370404438462499534570583
70.39345740085367186
ReMuS403357400833570125163195
|4241574008315
Registr426957400833570110125151174195
pacientů447757400833971104119153191213250
s4740574008326
roztroušenou47795740083215886111132169207233268306344382
sklerózou.51745740083265672107128165193231269282
Available54695740083407110411939345840083154786102137
from:40865840083194178136148
https://www.multiplesclerosis.cz/.42505840083375983123149162189209260314367378436474489512527566582617644676691726747784811826852866898928956962